

Aureothin Antibiotic Analogues as New Antiparasitic Agents






INTRODUCTION

Neglected diseases are a group of infectious, genetic, and nutritional conditions that disproportionately affect populations in remote areas of the world, often characterized by extreme poverty and limited access to healthcare services.






Miguel Villarreal-Parra, Guillermo R. Labadie.

Instituto de Química Rosario (CONICET), Suipacha 531, S2002LRK Rosario, Argentina. Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario (UNR).

One such disease is **American trypanosomiasis**, also known as Chagas disease, which is caused by the parasite *Trypanosoma cruzi*. The primary mode of transmission occurs through the feces of infected triatomines.¹ However, alternative transmission routes have also been reported, including blood transfusions, organ transplantation, and vertical transmission from mother to fetus during pregnancy.

In the search for new therapeutic candidates, Aureothin, a polyketide antibiotic first isolated over 50 years ago from Streptomyces thioluteus,² has gained attention due to its versatile biological activities.³



CONCLUSIONS

We successfully obtained and characterized six key reaction intermediates essential for the synthesis of multiple proposed compound libraries. This effort resulted in the production of 12 final 1,2,3-triazole 1,4-disubstituted analogues with yields exceeding 66%, and 11 amine-type analogues with yields surpassing 77%. The spatial distribution of the synthesized analogues demonstrates excellent coverage of the chemical space, providing valuable insights into the applied substitutions and designed molecules. Additionally, the integration of computational chemistry and pharmacokinetic property screening has enabled significant reductions in experimental costs, facilitating the targeted

- 1. Telleria, J.; Tabayrenc, M., American Trypanosomiasis Chagas Disease, 2nd Editión, Elsevier. 2017 3. Taniguchi, M.; Watanabe, M.; Nagai, K.; Suzumura, K.; Suzuki, K.; Tanaka, A. J. Antibiot. 2000, 53, 84
- 4. Otoguro, K.; Ishiyama, A.; Namatame, M.; Nishihara, A.; Furusawa, T.; Masuma, R.; Shiomi, K.; Takahashi, Y.; Yamada, H.; Omura, S. J. Antibiot. 2008, 61, 372.

Collection Synthesized

Currently, the collections of synthesized analogues are being tested against Malaria. We also aim to carry out biological assays against